ProteoStasis Therapeutics: $45 million first round, video interview with CEO

In late August, the Globe was the first to cover a new Cambridge biotech company, ProteoStasis Therapeutics, as it emerged from stealth mode and announced a first round of financing of $45 million, from firms like HealthCare Ventures, NEA, Fidelity BioSciences, Genzyme and Novartis.

Here's the video... an interview with ProteoStasis CEO David Pendergast:



And here's the official press release, and some coverage of the company from BioWorld.